Sistemic Ltd commences strategic growth plan

Building on the success of its analytical approach to microRNA (miRNA) profiling technologies, Scottish-based, Sistemic Ltd, (Glasgow,) has embarked on a major expansion programme which will bring additional key scientific and bioinformatic staff and a move to a larger dedicated facility forming the company’s new global headquarters. The new Glasgow site will enable faster completion of current contracts, provide capacity for acquired and future business and also support the company’s expansion of its key internal R&D programmes in drug toxicology and stem cell characterisation.

The company, formed in 2008, is also growing its US commercial operations, developing its Boston location and opening an office in California. Jim Reid, Sistemic Chairman and CEO said "We are delighted that things are going so well for the company especially when so many businesses are downsizing or finding life tough. It is a real endorsement of the unique technology we are developing and the customer-centric approach we take to our business.”

Dr Verna McErlane, Director of Commercial Operations, added; "We are committed to global expansion and see the developments in the US as key to providing customers with local support and dedicated resources aimed at the world’s largest market."

Dr David Mallinson, who previously worked for Merck Sharpe Dohme (MSD), joined the team on 1 May, as a Senior Scientist and will lead new projects at the expanded facility. Dr Max Bylesjo, who previously worked for ALMAC group join on 1 July, as a Senior Bioinformatician and will focus on continuing the development of Sistemic’s data processing technology. The company is currently seeking additional staff in anticipation of continued growth.

The new Sistemic headquarters will dedicate 60% of its space to new laboratory facilities, equipped with stateof- the-art technology, and 40% as new commercial areas.

The company’s core products include capability in the screening of drug discovery lead compounds to determine whole cell response to various chemistries as well as cell characterisation, QC monitoring, purity, potency and pluripotentcy assessment of cell lines.